Silo Pharma (NASDAQ:SILO) Announces Earnings Results

Silo Pharma (NASDAQ:SILO) released its earnings results on Thursday. The company reported ($0.76) EPS for the quarter, FiscalAI reports. Silo Pharma had a negative net margin of 6,726.39% and a negative return on equity of 88.40%.

Silo Pharma Stock Up 3.9%

NASDAQ SILO traded up $0.12 during trading hours on Thursday, hitting $3.22. The company’s stock had a trading volume of 22,511 shares, compared to its average volume of 200,719. The stock has a fifty day moving average of $5.40 and a 200 day moving average of $5.58. Silo Pharma has a twelve month low of $2.75 and a twelve month high of $15.15. The firm has a market capitalization of $4.03 million, a P/E ratio of -0.50 and a beta of 0.71.

Institutional Trading of Silo Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its stake in shares of Silo Pharma by 134.6% in the 4th quarter. Geode Capital Management LLC now owns 92,905 shares of the company’s stock valued at $32,000 after purchasing an additional 53,309 shares during the period. Virtu Financial LLC acquired a new stake in shares of Silo Pharma during the third quarter worth $74,000. DRW Securities LLC acquired a new stake in shares of Silo Pharma during the fourth quarter worth $113,000. Finally, AdvisorShares Investments LLC grew its stake in shares of Silo Pharma by 64.3% during the fourth quarter. AdvisorShares Investments LLC now owns 599,507 shares of the company’s stock worth $204,000 after purchasing an additional 234,629 shares during the period. Institutional investors own 5.58% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised Silo Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Silo Pharma

Silo Pharma, Inc (NASDAQ:SILO) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel psychedelic and related synthetic therapies. Headquartered in New York City, the company applies proprietary chemistry and targeted drug delivery approaches to advance candidates that address critical unmet needs across oncology, neurology and mental health.

The company’s preclinical and early-stage clinical pipeline comprises several programs that explore serotonin receptor modulators, synthetic analogs of classic psychoactive compounds and neuroprotective agents.